Camzyos™(mavacamten) – New orphan drug approval
April 28, 2022 - Bristol Myers Squibb announced the FDA approval of Camzyos (mavacamten), for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.
Top